Skip to main content
Premium Trial:

Request an Annual Quote

Fisher, Luminex, eGene, Sigma-Aldrich, Pfizer, Illumina, Waters, Max Planck, Sequenom

Fisher, Luminex to Develop Molecular Dx Products
 
Fisher HealthCare, a division of Thermo Fisher Scientific, and Luminex will use Luminex’s xMAP instruments and assays to jointly identify molecular diagnostic applications, Luminex said last week.  
 
Luminex, which develop and manufacture resulting products, said that by granting Fisher the US rights to its xMAP technology it gains a sales avenue through Fisher’s sales teams, its “access to key clinical accounts,” and its “extensive logistics network.”
 
Financial terms of the deal were not released.
 

 
Fisher to Sell eGene’s Genetic Analyzer in Canada
 
Fisher Scientific Canada has agreed to market and sell eGene's genetic analyzers in Canada, eGene said last week.
 
EGene's HDA-GT12 genetic analysis system provides sample loading, electrophoresis, and data analysis in a bundled platform.
 
"Both companies have seen exciting business opportunities for our genetic analyzers" in Canada, said eGene director of sales David Molnar in a statement.
 
Fisher Scientific Canada is a division of Thermo Fisher Scientific.
 

 
Sigma-Aldrich Licenses RNAi Technology to Pfizer
 
Sigma-Aldrich last week said it has granted Pfizer non-exclusive rights to its DNA-directed RNAi technology.
 
The agreement will allow Pfizer’s to use Sigma’s ddRNAi at any of its worldwide operations, Sigma said.
 
Sigma said it has exclusively licensed ddRNAi applications from Australian company Benitec and Australia’s Commonwealth Scientific and Industrial Research Organization.  
Financial terms of the agreement were not released.
 

 
Illumina to Collaborate with OntarioHospital on Molecular Tests
 
Illumina this week said that it will work with the Children's Hospital of Eastern Ontario to develop molecular tests that would screen infants for spinal muscular atrophy and blood diseases.
 
Under the terms of the agreement, Illumina will hold the commercial rights for any assays it develops with the CHEO, which is located in Ottawa.
 
The research collaboration calls for Illumina to use its VeraCode technology on its BeadXpress reader initially to screen for hemaglobinopathies, which are genetic conditions causing blood disorders such as sickle-cell anemia and thalassemia. 
 
Illumina said that spinal muscular atrophy is the number-one genetic killer of infants and toddlers, but added that there is hope that it may be treatable if the mutation causing it is detected early enough.
 
The company said CHEO screens roughly 135,000 newborns for 27 different diseases every year.
 

 
Waters Sells Synapt HDMS Instrument to Max Planck
 
The Max Planck Institute of Biochemistry recently received one of Waters' mass spec systems, the Milford, Mass.-based company said last week.
 
The Department of Cellular Biochemistry at the Martinsried, Germany-based institute will use the Synapt High Definition MS system to study the role of proteins in brain-wasting diseases such as Huntington's disease.
 
Manajit Hayer-Hartl, director and principal investigator for the department, said in a statement that the system will allow the researchers to characterize proteins of interest in great detail and said the ability to "separate species by ion mobility greatly enhances the appeal of this system."
 
Financial terms of the deal were not released.
 

 
Sequenom Sells MassArray Analyzers in S. Korea, Singapore
 
Sequenom sold three of its MassArray analyzers in South Korea in the fourth quarter of 2006, the company said this week.
 
The sales were made through Bioneer, a Daejeon-based genomics research products and services company that signed an exclusive deal with Sequenom in September 2006 to market and distribute the MassArray in South Korea.  
 
Sequenom said Bioneer sold one of its analysis systems to National Cancer Center of the Republic of Korea, but did not disclose the two other customers.
 
Bioneer president and CEO Han-Oh Park said the fourth-quarter sales “represent increased demand we are seeing in South Korea for fine mapping genetic analysis solutions, and for life sciences research tools in general.”
 
The Genome Institute of Singapore also has purchased two of Sequenom’s MassArray systems and will use them with the company’s iPLEX Gold genotyping assay, Sequenom said in a separate announcement this week.
 
The institute also will use Sequenom’s EpiTYPER epigenetic assay, used to study DNA methylation for cancer research.
 
GIS senior investigator Edison Liu said the institute will use the tools in its studies of population genetics, fine mapping analysis, and breast cancer. 
 
Financial terms of the deal were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.